1. Aliment Pharmacol Ther. 2011 Dec;34(11-12):1318-27. doi: 10.1111/j.1365-2036.2011.04866.x. Epub 2011 Sep 29. 1. Aliment Pharmacol Ther. 2009 May 1;29(9):921-7. doi: 10.1111/j.1365-2036.2009.03955.x. Epub 2009 Feb 10. Differing effect of systemic anti psoriasis therapies on platelet physiology – a case report and review of literature. Aliment Pharmacol Ther 1997,11(2):237247.
Si votre psoriasis est svre, nous vous recommandons de consulter un dermatologue. Rgime alimentaire pour soulager le de rhumatisme psoriasique. Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease Aliment Pharmacol Ther 2009; 29: 921-927 cross-ref Click here to see the Library, 5de Gannes G. However, because only few patients on anti-TNF therapy develop psoriasis, a genetic predisposition is likely. Aliment Pharmacol Ther, 34 (2011), pp. 5158.
Rogler G, Herfarth H, Hibi T, Nielsen OH (eds): Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease. Psoriasis is a common chronic skin disorder most commonly characterized by well-demarcated erythematous plaques with silver scale (). Aliment Pharmacol Ther 2011; 34:1318. Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study. We assessed the cumulative incidence of anti-TNF-induced cutaneous adverse reactions in IBD patients, their risk factors, their dermatological management, and their outcome in a large cohort of IBD patients. Aliment Pharmacol Ther 2013;38:10021024.